​

Novo Nordisk (NVO) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

NVO Stock Forecast

Novo Nordisk (NVO) stock forecast, based on 39 Wall Street analysts, predicts a 12-month average price target of $47.00, with a high of $54.00 and a low of $42.00. This represents a 23.62% increase from the last price of $38.02.

- $30 $60 $90 $120 $150 High: $54 Avg: $47 Low: $42 Last Closed Price: $38.02

NVO Stock Rating

Novo Nordisk stock's rating consensus is Buy, based on 39 Wall Street analysts. The breakdown includes 1 Strong Buy (2.56%), 22 Buy (56.41%), 13 Hold (33.33%), 3 Sell (7.69%), and 0 Strong Sell (0.00%).

Buy
Total 39 3 13 22 1 Strong Sell Sell Hold Buy Strong Buy

NVO Price Target Upside V Benchmarks

TypeNameUpside
StockNovo Nordisk23.62%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks1.85%

Price Target Trends

1M3M12M
# Anlaysts-210
Avg Price Target-$51.00$52.10
Last Closing Price$38.02$38.02$38.02
Upside/Downside-34.14%37.03%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 261651-13
Feb, 26-652-13
Jan, 261542-12
Dec, 251632-12
Nov, 251622-11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 05, 2026BMO Capital$45.00$47.19-4.64%18.36%
Jan 26, 2026Evan SeigermanBMO Capital$57.00$63.80-10.66%49.92%
Dec 10, 2025HSBC$54.00$46.3616.48%42.03%
Dec 03, 2025Thibault BoutherinMorgan Stanley$42.00$47.43-11.45%10.47%
Nov 25, 2025Evan SeigermanBMO Capital$46.00$44.972.29%20.99%
Oct 14, 2025Evan SeigermanBMO Capital$55.00$57.50-4.35%44.66%
Oct 01, 2025HSBC$70.00$59.1718.30%84.11%
Sep 29, 2025Morgan Stanley$47.00$55.61-15.48%23.62%
Jul 31, 2025HSBC$57.00$48.8916.59%49.92%
Jul 23, 2025Jailendra SinghTruist Financial$48.00$70.03-31.46%26.25%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 24, 2026NordeaHolddowngrade
Feb 23, 2026Deutsche BankBuyHolddowngrade
Feb 12, 2026JefferiesUnderperformHoldupgrade
Feb 05, 2026BMO CapitalMarket PerformMarket Performhold
Feb 03, 2026Cowen & Co.BuyBuyhold
Jan 27, 2026CitigroupNeutralinitialise
Jan 22, 2026Goldman SachsBuyBuyhold
Jan 14, 2026BMO CapitalMarket PerformMarket Performhold
Jan 09, 2026CICCOutperforminitialise
Dec 23, 2025BMO CapitalMarket PerformMarket Performhold

Financial Forecast

EPS Forecast

$5 $14 $23 $32 $41 $50 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$20.79$24.51$18.67-----
Avg Forecast$10.30$12.16$18.11$22.71$27.91$33.73$37.72$42.84
High Forecast$10.69$12.71$18.31$23.50$29.89$35.87$40.11$45.55
Low Forecast$9.85$11.25$17.77$21.91$25.33$33.58$37.56$42.66
Surprise %101.84%101.56%3.09%-----

Revenue Forecast

$100B $190B $280B $370B $460B $550B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$140.80B$176.95B$232.26B-----
Avg Forecast$139.79B$175.68B$226.80B$287.17B$350.19B$407.94B$443.79B$496.87B
High Forecast$143.80B$181.72B$229.04B$292.28B$359.69B$427.83B$465.43B$521.10B
Low Forecast$135.04B$165.59B$225.24B$282.07B$340.69B$406.60B$442.34B$495.24B
Surprise %0.72%0.72%2.41%-----

Net Income Forecast

$0 $90B $180B $270B $360B $450B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$47.76B$55.52B$83.68B-----
Avg Forecast$292.37B$343.87B$370.75B$102.06B$125.43B$151.60B$169.56B$192.55B
High Forecast$350.84B$412.64B$444.90B$105.63B$134.36B$161.21B$180.31B$204.76B
Low Forecast$233.89B$275.09B$296.60B$98.50B$113.84B$150.96B$168.84B$191.73B
Surprise %-83.67%-83.85%-77.43%-----

NVO Forecast FAQ

Is Novo Nordisk stock a buy?

Novo Nordisk stock has a consensus rating of Buy, based on 39 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 22 Buy, 13 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that Novo Nordisk is a favorable investment for most analysts.

What is Novo Nordisk's price target?

Novo Nordisk's price target, set by 39 Wall Street analysts, averages $47 over the next 12 months. The price target range spans from $42 at the low end to $54 at the high end, suggesting a potential 23.62% change from the previous closing price of $38.02.

How does Novo Nordisk stock forecast compare to its benchmarks?

Novo Nordisk's stock forecast shows a 23.62% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the drug manufacturers - general stocks industry (1.85%).

What is the breakdown of analyst ratings for Novo Nordisk over the past three months?

  • March 2026: 7.69% Strong Buy, 46.15% Buy, 38.46% Hold, 7.69% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 46.15% Buy, 38.46% Hold, 15.38% Sell, 0% Strong Sell.
  • January 2026: 8.33% Strong Buy, 41.67% Buy, 33.33% Hold, 16.67% Sell, 0% Strong Sell.

What is Novo Nordisk’s EPS forecast?

Novo Nordisk's average annual EPS forecast for its fiscal year ending in December 2024 is $22.71, marking a 21.64% increase from the reported $18.67 in 2023. Estimates for the following years are $27.91 in 2025, $33.73 in 2026, $37.72 in 2027, and $42.84 in 2028.

What is Novo Nordisk’s revenue forecast?

Novo Nordisk's average annual revenue forecast for its fiscal year ending in December 2024 is $287.17B, reflecting a 23.64% increase from the reported $232.26B in 2023. The forecast for 2025 is $350.19B, followed by $407.94B for 2026, $443.79B for 2027, and $496.87B for 2028.

What is Novo Nordisk’s net income forecast?

Novo Nordisk's net income forecast for the fiscal year ending in December 2024 stands at $102.06B, representing an 21.96% increase from the reported $83.68B in 2023. Projections indicate $125.43B in 2025, $151.6B in 2026, $169.56B in 2027, and $192.55B in 2028.